Atanasio
Pandiella Alonso
Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (65)
2024
-
ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression
International Journal of Molecular Sciences, Vol. 25, Núm. 6
2023
-
An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer
Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 200
-
Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer
International Journal of Biological Sciences, Vol. 19, Núm. 6, pp. 1731-1747
-
Considerations for the clinical development of immuno-oncology agents in cancer
Frontiers in immunology, Vol. 14, pp. 1229575
-
Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications
Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257
2022
-
ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology
Cancers, Vol. 14, Núm. 14
-
Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
Cancer Research, Vol. 82, Núm. 3, pp. 447-457
-
Novel adcs and strategies to overcome resistance to anti-her2 adcs
Cancers, Vol. 14, Núm. 1
-
Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis
Therapeutic Advances in Medical Oncology, Vol. 14
-
Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer
Cancer research, Vol. 82, Núm. 24, pp. 4670-4679
-
Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates
Frontiers in Immunology, Vol. 12
-
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Molecular Cancer Research, Vol. 20, Núm. 7, pp. 1108-1121
2021
-
Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer
npj Precision Oncology, Vol. 5, Núm. 1
-
In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer
Cellular Oncology, Vol. 44, Núm. 3, pp. 569-580
-
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
-
Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer
Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5096-5108
-
Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation
International Journal of Molecular Sciences, Vol. 22, Núm. 8
2020
-
Breast cancer heterogeneity and response to novel therapeutics
Cancers, Vol. 12, Núm. 11, pp. 1-16
-
Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors
Frontiers in Oncology, Vol. 9